INTEGRATED EXPRESSION PROFILING CHARACTERIZES BIOLOGICAL HETEROGENEITY IN REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND THE RISK OF RICHTER TRANSFORMATION
EHA Learning Center, Johannes Bloehdorn, 214581
IN-SILICO DISSECTION OF DIFFUSE LARGE B CELL LYMPHOMA MICROENVIRONMENT PROVIDES A 45-GENE PANEL FOR RISK STRATIFICATION
EHA Learning Center, Sabino Ciavarella, 214643
GENOMIC CHARACTERISATION OF CIRCULATING TUMOUR DNA (CTDNA) PREFERENTIALLY IDENTIFIES EARLY CLINICALLY RELEVANT GENOMIC EVENTS AND PROVIDES INSIGHT INTO THE CLONAL ARCHITECTURE OF LYMPHOID MALIGNANCY
EHA Learning Center, Piers Blombery, 214644
FUNCTIONAL CHARACTERIZATION OF ABERRANT FAT1 EXPRESSION IN T-ALL
EHA Learning Center, Sven Liebig, 215243
“TRIPLE NEGATIVE” ACUTE GENE EXPRESSION CLUSTERING IDENTIFY NEW ADULT LYMPHOBLASTIC LEUKEMIA SUBGROUPS
EHA Learning Center, Anna Ferrari, 215244
IDENTIFICATION OF BCR-ABL-LIKE PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY REAL-TIME PCR
EHA Learning Center, Grigory Tsaur, 215260
DELIVERY OF INTRATHECAL METHOTREXATE CHEMOPROPHYLAXIS TO ADULTS AND TYA PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA – AN AUDIT OF FACTORS AFFECTING PROTOCOL ADHERENCE
EHA Learning Center, Sven Armin Sommerfeld, 215261
THE ROLE OF STAT3Β IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Petra Aigner, 215277
DISSECTING INTRA-TUMOR HETEROGENEITY IN ACUTE MYELOID LEUKEMIA THROUGH LEUKEMIA STEM CELL-ASSOCIATED MIRNA SIGNATURES AND SINGLE-CELL RNA TRANSCRIPTIONAL PROFILING
EHA Learning Center, Matteo Maria Naldini, 215278
ASSESSMENT OF HIGH-RISK MOLECULAR MARKERS IN INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA AS DEFINED BY 2010 ELN RISK CLASSIFICATION
EHA Learning Center, Ekaterina Panina, 215294
MOLECULAR PROLIFE BY NEXT GENERATION SEQUENCING OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: CLINICAL RESULTS FROM THE PROSPECTIVE TRIAL 02/06 OF THE NORTHERN ITALY LEUKEMIA GROUP (NILG)
EHA Learning Center, Orietta Spinelli, 215295
AN EVALUATION OF CONTROL REGIMENS IN A GROUP OF HIGH RISK OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA FROM TWO COOPERATIVE GROUPS: DATA FROM THE UK NCRI AND DUTCH HOVON STUDIES
EHA Learning Center, Robert Hills, 215310
TP53 ALTERATIONS AND MONOSOMAL KARYOTYPE IN OLDER UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH DECITABINE
EHA Learning Center, Heiko Becker, 215311
CLINICAL CHARACTERISTICS AND PROGNOSIS OF 34 CASES OF ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION AND MLL GENE REARRANGEMENT
EHA Learning Center, Jian Ouyang, 215326
PROGNOSTIC RELEVANCE OF FLT3, NPM1, DNMT3A, IDH1/2 GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS
EHA Learning Center, Irina Martynkevich, 215327
RITUXIMAB, BENDAMUSTINE AND CYTARABINE (R-BAC) IN PATIENTS WITH RELAPSED-REFRACTORY AGGRESSIVE B- CELL LYMPHOMA
EHA Learning Center, Maria Chiara Tisi, 215342
A PROPENSITY SCORE ANALYSIS SHOWS THAT RITUXIMAB DOSE-ADJUSTED EPOCH IMPROVES PROGRESSION-FREE SURVIVAL OF YOUNG PATIENTS AFFECTED BY DOUBLE EXPRESSOR DIFFUSE LARGE B -CELL LYMPHOMAS
EHA Learning Center, Anna Guidetti, 215343
HIGH INCIDENCE OF CARDIOMYOPATHY IN PATIENTS RECEIVING CHOEP14 - POSSIBLE SYNERGISTIC CARDIOTOXICITY OF DOSE-DENSE DOXORUBICIN AND ETOPOSIDE
EHA Learning Center, Igor Aurer, 215358
PROGNOSTIC IMPACT OF SITES OF EXTRANODAL INVOLVEMENT IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA
EHA Learning Center, Norihito Inoue, 215359
PHASE IB STUDY OF THE CXCR4 ANTAGONIST BL8040 COMBINED WITH IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH APLASTIC ANEMIA
EHA Learning Center, Tapan Kadia, 215374
CLINICAL EFFICACY OF THERAPIES FOR TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A RETROSPECTIVE COHORT STUDY IN MULTIPLE HOSPITALS
EHA Learning Center, Guangsheng He, 215375
SELECTIVE CHK1 INHIBITOR MU380 EXHIBITS SINGLE-AGENT ACTIVITY AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA CELLS WITH TP53 MUTATIONS
EHA Learning Center, Miroslav Boudny, 215390
PI3K INHIBITORS INHIBIT TUMOR MICROENVIRONMENT (TME) REGULATION OF PROGRAMMED DEATH-1 (PD1) AND PDL1/2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A POTENTIAL APPROACH TO OVERCOME TUMOR-INDUCED TOLERANCE
EHA Learning Center, Fortunato Morabito, 215391
NOTCH1 MUTATIONS ARE AN INDEPENDENT PROGNOSTIC FACTOR IN IBRUTINIB- TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS
EHA Learning Center, Giovanni DEL POETA, 215407
PROGNOSTIC IMPACT OF POSITIVE MINIMAL RESIDUAL DISEASE (MRD) BELOW THE THRESHOLD OF 0.01% IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS AFTER IMMUNOCHEMOTHERAPY: STUDY OF A DATASET FROM 3 FILO TRIALS
EHA Learning Center, Remi Letestu, 215408
ENRICHMENT OF ASXL1 PATHOGENIC VARIANTS AMONG PRIMARY REFRACTORY CML PATIENTS
EHA Learning Center, Kristin Gustafsson, 215423
THE PIVOTAL ROLE OF INSULIN-LIKE GROWTH FACTOR PATHWAY AS A THERAPEUTIC TARGET IN ABL TYROSINE KINASE INHIBITOR RESISTANT LEUKEMIA CELLS
EHA Learning Center, Seiichi Okabe, 215424
ULTRA-SENSITIVE DETECTION OF TYROSINE KINASE INHIBITOR RESISTANT MUTATIONS IN CHRONIC MYELOID LEUKEMIA PATIENTS USING MISEQ ILLUMINA NEXT GENERATION SEQUENCING PLATFORM
EHA Learning Center, Marianna Romžová, 215439
PEG-INTERFERON ΑLPHA 2B CAN IMPROVE MOLECULAR RECURRENCES IN THE TREATMENT-FREE REMISSION; A PILOT STUDY WITH 18-MONTH FOLLOW-UP
EHA Learning Center, Manuel Ayala, 215440
SUCCESSFUL TREATMENT OF MEGALOBLASTIC ANEMIA WITH BONE MARROW MYELODYSPLASIA IN LESCH-NYHAN SYNDROME
EHA Learning Center, Maciej Machaczka, 215456
CORD BLOOD DERIVED GAMMA-DELTA T CELLS CAN BE EXPONENTIALLY EXPANDED IN VITRO TO INDUCE POTENT CYTOTOXICITY AGAINST HUMAN ACUTE MYELOID LEUKEMIA CELLS
EHA Learning Center, Alice Cheung, 215457
TRANSCRIPTION FACTORS REGULATE DNA METHYLATION DYNAMICS IN HEMATOPOIETIC DEVELOPMENT
EHA Learning Center, Takahiro Suzuki, 215472
CANONICAL NOTCH SIGNALING IS DISPENSIBLE FOR ADULT STEADY-STATE AND STRESS MYELO-ERYTHROPOIESIS
EHA Learning Center, SARA DUARTE, 215473
DIFFERENTIAL DIAGNOSIS OF ENLARGED LYMPH NODE USING ULTRASOUND ELASTOSONOGRAPHY
EHA Learning Center, Novella Pugliese, 215488
FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDY
EHA Learning Center, Andrea Gallamini, 215489
ONE-YEAR SURVIVAL AMONG PATIENTS WITH HEMATOLOGICAL DISEASE ADMITTED TO THE INTENSIVE CARE UNIT: A NATIONWIDE COHORT STUDY
EHA Learning Center, Peter Asdahl, 215505
PREVALENCE AND RISK FACTORS OF RESISTANT GRAM-NEGATIVE BACILLI COLONIZATION AND INFECTION IN HOSPITALIZED HAEMATOLOGICAL PATIENTS
EHA Learning Center, Ana González Rodríguez, 215506
CASTLEMAN DISEASE WITH THE EXPERIENCE OVER 17 YEARS
EHA Learning Center, Guray Saydam, 215521
EFFECTIVENESS OF DIFFERENT IRON ORAL FORMULATION IN IRON DEFICIENCY ANEMIA DUE TO GASTROINTESTINAL BLEEDING: MULTICENTRIC RANDOMIZED STUDY.
EHA Learning Center, GIULIO GIORDANO, 215522
RENAL FUNCTION IN TRANSFUSION-DEPENDENT Β-THALASSEMIA PATIENTS: A DECADE OF FOLLOW-UP AND COMPARISON BETWEEN CHELATION REGIMES
EHA Learning Center, Carina Levin, 215523
IMPACT OF RED BLOOD CELL TRANSFUSION RATE, ADJUSTED BY THERAPEUTIC INTERVENTIONS, ON PROGRESSION-FREE SURVIVAL IN LOWER RISK MDS PATIENTS WITHIN THE EUROPEAN LEUKEMIANET MDS REGISTRY
EHA Learning Center, Louise de Swart, 215537
EXPRESSION PATTERN OF LONG-NONCODING RNAS ALTERS IN DIFFERENT FORMS OF MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Katarina Szikszai, 215538
MDS WITH P53 DYSFUNCTION: A NEW PROGNOSTIC AND PREDICTIVE CATEGORY. A STUDY FROM THE ITALIAN MDS CLINICAL NETWORK
EHA Learning Center, Marianna rossi, 215539
LOW RISK MDS WITHOUT RING SIDEROBLASTS. CLINICAL AND BIOLOGICAL CHARACTERIZATION FROM THE SPANISH GROUP OF MDS.
EHA Learning Center, Félix López Cadenas, 215553
SEROTONIN RECEPTOR TYPE 1B CONSTITUTES A THERAPEUTIC TARGET FOR MDS AND CMML.
EHA Learning Center, Antònia BANÚS MULET, 215554
INTENSIVE CHEMOTHERAPY (IC) IS MORE EFFECTIVE THAN HYPOMETHYLATING AGENTS (HMA) FOR THE TREATMENT OF YOUNGER PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ELEVATED BONE MARROW BLASTS
EHA Learning Center, Paola Strati, 215555
BONE MARROW MACROPHAGES IN PATIENTS WITH MULTIPLE MYELOMA IN COMPLETE REMISSION RETAIN PRO-TUMOR M2 PHENOTYPE
EHA Learning Center, Ester Lozano, 215570
PTC-028 DEMONSTRATES POTENT PRE-CLINICAL ACTIVITY AND PROVIDES A NOVEL OPPORTUNITY TO MODULATE BMI1 IN MULTIPLE MYELOMA
EHA Learning Center, Heinz Ludwig, 215571
ARGININE DEPRIVATION SUSTAINS PLASMA CELL FITNESS AND BIOENERGETICS IN MULTIPLE MYELOMA
EHA Learning Center, Alessandra Romano, 215572
PROTEIN KINASE CK1 ALPHA MODULATES PROSURVIVAL AUTOPHAGY IN MULTIPLE MYELOMA
EHA Learning Center, Marilena Carrino, 215586
SERUM LIPID METABOLOMICS AS AN USEFUL BIOMARKER PREDICTING FOR THE EFFICACY OF BORTEZOMIB TREATMENT AND PERIPHERAL NEUROPATHY IN PATIENTS WITH MULTIPLE MYELOMA
EHA Learning Center, Masaki Ri, 215587
CIRCULATING SOLUBLE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS REFLECTS RENAL FUNCTION IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TREATED WITH BORTEZOMIB-BASED THERAPY
EHA Learning Center, Evangelos Terpos, 215588
NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AS A BIOMARKER IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: DATA FROM A PHASE II TRIAL OF POMALIDOMIDE PLUS DEXAMETHASONE
EHA Learning Center, Katja Weisel, 215602
REAL WORLD CLINICAL IMPLICATIONS OF THE LIMITATIONS ASSOCIATED WITH THE REVISED INTERNATIONAL STAGING SYSTEM: UNSELECTED PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NOVEL AGENTS IN AGEING SOCIETY
EHA Learning Center, Yoshiaki Abe, 215603
EVALUATION OF MINIMAL RESIDUAL DISEASE USING NEXT GENERATION FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS
EHA Learning Center, Ioannis Kostopoulos, 215604
SUBCUTANEOUS DARATUMUMAB (DARA SC) + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: SAFETY RUN-IN RESULTS OF ANDROMEDA
EHA Learning Center, Giampaolo Merlini, 215618
DISEASE ASSESSMENT BY PET-CT PLUS FLOW CYTOMETRY IN MULTIPLE MYELOMA IDENTIFIES PATIENTS WITH DIFFERENT SURVIVAL OUTCOMES
EHA Learning Center, Rafael Alonso Fernández, 215619
PREDICTORS OF HEMATOLOGIC AND ORGAN RESPONSE IN AL AMYLOIDOSIS
EHA Learning Center, Giovanni Palladini, 215620
OPTIMISING TREATMENT FOR HIGH-RISK MYELOMA IN A STRATIFIED MULTI-CENTRE TRIAL: EXPERIENCE FROM MUKNINE OPTIMUM STUDY
EHA Learning Center, Martin Kaiser, 215634
ASYMPTOMATIC HEART INVOLVEMENT IN AL AMYLOIDOSIS
EHA Learning Center, Marco Basset, 215635
RANDOMIZED CLINICAL TRIAL (RCT) REPRESENTATIVENESS & OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REAL WORLD (RW) PATIENTS: COMPARISON OF ASPIRE, TOURMALINE-MM1, POLLUX, & ELOQUENT RCTS
EHA Learning Center, Dorothy Romanus, 215636
IS ANEMIA THE MAIN SURVIVAL MARKER IN PATIENTS WITH MYELOFIBROSIS IN THE RUXOLITINIB ERA?
EHA Learning Center, María Isabel Montero, 215650
DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER EXPERIENCE OF THE RETE EMATOLOGICA LOMBARDA (IRON-M STUDY)
EHA Learning Center, Elena Maria Elli, 215651
MYELOID AND LYMPHOID NEOPLASMS ASSOCIATED WITH PDGFRA AND PDGFRB REARRANGEMENTS: CLINICAL CORRELATES AND SURVIVAL OUTCOMES.
EHA Learning Center, Abhishek Mangaonkar, 215652
THE “MYMPN” PATIENT REGISTRY: VALIDATION OF A PROSPECTIVE MYELOPROLIFERATIVE NEOPLASM PATIENT REGISTRY
EHA Learning Center, Robyn Scheber, 215666
THE RELATIONSHIP OF BODY MASS INDEX TO SYMPTOM BURDEN IN THE MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Robyn Scheber, 215667
MANAGEMENT AND OUTCOME OF PATIENTS DIAGNOSED WITH POLYCYTHEMIA VERA IN YOUNG AGE
EHA Learning Center, Giulia Bogoni, 215668
PD1-TIM3+ CELLS ARE THE PREDOMINANT POPULATION OF EXHAUSTED CD8+ CELLS IN FOLLICULAR LYMPHOMA WITH HIGH REACTIVATION POTENTIAL
EHA Learning Center, Theodora Anagnostou, 215683
ENZYME-FREE DIGITAL COUNTING OF ENDOGENOUS CIRCULAR RNA MOLECULES IN FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUES FROM PATIENTS WITH B-CELL MALIGNANCIES
EHA Learning Center, Mette Dahl, 215684
PROTEIN KINASE CK1 ΑLPHA SUSTAINS MANTLE CELL LYMPHOMA SURVIVAL BY IMPINGING ON BCR-LINKED SIGNALING PATHWAYS
EHA Learning Center, Sabrina Manni, 215685
FACTORS AFFECTING THROMBOPOIETIN RECEPTOR AGONIST REINITIATION AFTER DISCONTINUATION IN WELL-CONTROLLED PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN THE UK: RESULTS FROM A MODIFIED DELPHI CONSENSUS PANEL
EHA Learning Center, Anuja Roy, 215700
IMMATURE PLATELET FRACTION (IPF): AN INTERESTING TOOL TO INVESTIGATE THROMBOCYTOPENIA
EHA Learning Center, Zoe Van de Wyngaert, 215701
INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM IN EGYPTIAN CHILDREN AND ADOLESCENTS WITH IMMUNE THROMBOCYTOPENIA: ASSOCIATION WITH DISEASE SUSCEPTIBILITY, RESPONSE TO THERAPY AND OUTCOME
EHA Learning Center, Mohammed Mostafa Kamel Al-tawil, 215702
COST COMPARISON OF TREATMENT STRATEGIES FOLLOWING INITIATION WITH RD VERSUS VMP PLUS DARATUMUMAB IN NEWLY DIAGNOSED PATIENTS INELIGIBLE FOR ASCT
EHA Learning Center, Graham Jackson, 215717
IMPROVABLE LIFESTYLE FACTORS IN LYMPHOMA SURVIVORS
EHA Learning Center, Carla Minoia, 215718
QUALITY OF LIFE IN ADVANCED-STAGE,ASYMPTOMATIC,NON-BULKY FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB SHOWS SIGNIFICANT IMPROVEMENT COMPARED WITH WATCHFUL-WAITING: PHASE 3 RANDOMISED INTERNATIONAL STUDY
EHA Learning Center, Maria A V Marzolini, 215719
QUALITY OF LIFE IS REDUCED IN PATIENTS WITH (SUSPECTED) PLATELET FUNCTION DISORDERS
EHA Learning Center, Maaike Blaauwgeers, 215733
PALLIATIVE CARE INDICATION IN ONCOHEMATOLOGIC PATIENTS: A COMPARISON TO SOLID TUMOR PATIENTS
EHA Learning Center, Lucia Morais, 215734
COST PER MEDIAN MONTH OF PROGRESSION‐FREE SURVIVAL FOR DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE COMPARED WITH CARFILZOMIB PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Eric Maiese, 215735
PD-1 OVEREXPRESSION ON BONE MARROW RESIDENT CD8+ MEMORY T-CELL SUBSETS COULD BE A PREDICTABLE MARKER FOR LEUKEMIA RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.
EHA Learning Center, Mikhail Drokov, 215750
OUTCOME OF SECOND SOLID CANCER AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COHORT STUDY ON 4065 PATIENTS ON BEHALF OF THE COMPLICATIONS AND QUALITY OF LIFE WORKING PARTY OF THE EBMT
EHA Learning Center, André Tichelli, 215751
SIMILAR OUTCOMES OF REDUCED INTENSITY HAPLOIDENTICAL TRANSPLANTATION WHEN COMPARED TO MATCHED UNRELATED DONOR TRANSPLANT IN DIFFUSE LARGE B CELL LYMPHOMA. A JOINT ANALYSIS FROM CIBMTR-LC & EBMT-LWP.
EHA Learning Center, Anna Sureda, 215752
THE SIGNIFICANCE OF PERI-TRANSPLANTATION MINIMAL RESIDUAL DISEASE ASSESSED BY MULTIPARAMETER FLOW CYTOMETRY ON OUTCOMES FOR ADULT AML PATIENTS RECEIVING HAPLOIDENTICAL ALLOGRAFTS
EHA Learning Center, Jing Liu, 215766
CHANGES IN THE NUMBER OF BONE MARROW LESIONS AND TUMOUR MASS ON MRI IN PATIENTS WITH MM FOLLOWING AUTO-HSCT
EHA Learning Center, Maxim Solovev, 215767
ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE AMONG PATIENTS UNDERGOING ALLOGENEIC CELL TRANSPLANT FOR HEMATOLOGICAL MALIGNANCY IN THE UNITED STATES: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS
EHA Learning Center, Aliki Taylor, 215768
SEVERE PRE-ALLO-HSCT IRON OVERLOAD (IO), MEASURED BY LIVER MRI, SIGNIFICANTLY IMPAIRED THE PROCEDURE LONG-TERM OUTCOME
EHA Learning Center, VALLEJO LLAMAS JUAN CARLOS, 215782
INCIDENCE AND RISK FACTORS FOR THE DEVELOPMENT OF HEMORRHAGIC CYSTITIS ON HAPLOIDENTICAL TRANSPLANTATION
EHA Learning Center, Cynthia ACOSTA FLEITAS, 215783
THREE MONTH FULL WHOLE BLOOD AND MIXED T CELL CHIMERISM IS ASSOCIATED WITH SUPERIOR OUTCOMES IN REDUCED-INTENSITY ALEMTUZUMAB-BASED ALLOGENEIC STEM CELL TRANSPLANTS FOR HAEMATOLOGICAL MALIGNANCIES
EHA Learning Center, Alexandros Kanellopoulos, 215784
PRE- AND POST-TRANSFUSION COMPLEMENT ACTIVATION IN TRANSFUSION-DEPENDENT Β-THALASSAEMIA
EHA Learning Center, Eleni Gavriilaki, 215798
ASSOCIATION OF CLINICAL PHENOTYPE OF THALASSEMIA WITH COMMON FETAL HEMOGLOBIN VARIANTS IN LEBANESE PATIENTS BEARING THE CODON 29 ΒETA GENE MUTATION
EHA Learning Center, Ali Taher, 215799
THALASSEMIA PREVENTION PROGRAM IN DEVELOPING WORLD SCENARIO: 13 YEARS EXPERIENCE
EHA Learning Center, Kousar Perveen, 215800
C-TERMINAL FRAGMENTS OF NEUROPEPTIDES CHANGE INTERACTION OF BLOOD CELLS IN THROMBOGENESIS
EHA Learning Center, Maria Golubeva, 215815
COMPARATIVE STUDY OF DALTEPARIN SODIUM AND ACETYLSALICYLIC ACID IN PREVENTION OF ANTIPHOSPHOLID SYNDROM ASSOTIATED WITH RECURRENT PREGNANCY MISCARRIAGE.
EHA Learning Center, Dimitry Marinitch, 215816
LABORATORY CRITERIA FOR THE DIAGNOSTIC RELIABILITY OF TESTS FOR DETECTION OF LUPUS ANTICOAGULANT IN PATIENTS WITH SUSPECTED ANTIPHOSPHOLIPID SYNDROME
EHA Learning Center, Valeriia Krasivska, 215817
EVALUATION OF CORRELATION BETWEEN EARLY IMMATURE T-ALL IMMUNOPHENOTYPE, ABSENCE OF BIALLELIC DELETION OF TCR-Γ AND MEF2C EXPRESSION
EHA Learning Center, Jay SINGH, 215895
NATIONAL EARLY WARNING SCORE (NEWS), QUICK SEQUENTIAL (SEPSIS-RELATED) ORGAN FAILURE ASSESSMENT (QSOFA) AND MICROBIOLOGICAL EVALUATION IN FEBRILE NEUTROPENIA OF ACUTE MYELOID LEUKEMIA
EHA Learning Center, Barbara Nicolino, 215896
LENALIDOMIDE PLUS BENDAMUSTINE-RITUXIMAB DOES NOT OVERCOME THE ADVERSE IMPACT OF TP53 MUTATIONS IN MANTLE CELL LYMPHOMA
EHA Learning Center, Christian Winther Eskelund, 215897
DETECTION OF MYD88 AND CXCR4 MUTATIONS IN CELL-FREE DNA OF PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES
EHA Learning Center, Tina Bagratuni, 215911
NEXT-GENERATION SEQUENCING ALTERNATIVES FOR THE DETECTION AND QUANTIFICATION OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Alejandro Medina, 215912
CYCLIN D1-MEDIATED GENE EXPRESSION DYSREGULATION IMPACTS MANTLE CELL LYMPHOMA PATHOGENESIS
EHA Learning Center, Silvia Beà Bobet, 215913

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings